SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
Open Access
- 6 August 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (3), 2002114
- https://doi.org/10.1183/13993003.02114-2020
Abstract
Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption.https://bit.ly/3hCw5dqKeywords
This publication has 3 references indexed in Scilit:
- Preserving Clinical Trial Integrity During the Coronavirus PandemicJAMA, 2020
- Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung diseaseEuropean Respiratory Review, 2020
- Disease-specific clinical trials networks: the example of cystic fibrosisEuropean Journal of Pediatrics, 2016